Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Organto reported Q4 and 2026 financials, beating our expectations on revenue and gross margins, but missing slightly on EBITDA.</li>
<li>Revenue came in at $60.8M for 2025 and $14.9M for Q4, compared to our estimates of $60.1M and $14.2M, respectively.</li>
<li>Gross margins were 10.8% in Q4 vs. our 9.0%, reflecting meaningful improvements.</li>
</ul>


Organto reported Q4 and 2026 financials, beating our expectations on revenue and gross margins, but missing slightly on EBITDA.
Revenue came in at $60.8M for 2025 and $14.9M for Q4, compared to our estimates of $60.1M and $14.2M, respectively.
Gross margins were 10.8% in Q4 vs. our 9.0%, reflecting meaningful improvements.


OGO: Finishing 2025 with 194% YoY Revenue Growth

Organto Foods

OGO: Finishing 2025 with 194% YoY Revenue Growth